Search

Your search keyword '"Nytrova, Petra"' showing total 45 results
Start Over Author "Nytrova, Petra"
45 results on '"Nytrova, Petra"'

4. To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection

Author

Stastna, Dominika, Menkyova, Ingrid, Drahota, Jiri, Hrnciarova, Tereza, Kubala Havrdova, Eva, Vachova, Marta, Andelova, Michaela, Kleinova, Pavlina, Kovarova, Ivana, Krasulova, Eva, Preiningerova, Jana Lizrova, Novakova, Iveta, Novotna, Klara, Novotna, Martina, Nytrova, Petra, Pavlickova, Jana, Srpova, Barbora, Storey, Katerina, Ticha, Veronika, Tyblova, Michaela, Uher, Tomas, Vodehnalova, Karolina, and Horakova, Dana

Published
2022
Full Text
View/download PDF

5. Dysregulated Lipid Metabolism Networks Modulate T-cell Function in People with Relapsing Remitting Multiple Sclerosis

Author

Martin-Gutierrez, Lucia, primary, Waddington, Kirsty E, additional, Maggio, Annalisa, additional, Coelewij, Leda, additional, Oppong, Alexandra, additional, Yang, Nina, additional, Adriani, Marsilio, additional, Nytrova, Petra, additional, Farrell, Rachel, additional, Pineda-Torra, Inés, additional, and Jury, Elizabeth C, additional

Published
2024
Full Text
View/download PDF

7. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Author

Muñoz, Daniel Julio, Amor, Jorge David, Bocchiardo, Carolina, Danielle, Julieta Iourno, Laffue, Alfredo, Obregon, Carolina Daniela Diaz, Paez, Maria Fernanda, Perez, Roberto Martin, Rocchi, Viviana Ana Maria, Teijeiro, Loreley Deborah, Gómez, Jesica, Villa, Andres Maria, Aguirre, Florencia, Fernández, Victoria Carla, Goicoechea, Ramon F., Melamud, Luciana, Stillman, Ana, de Virgiliis, Mariana, Cassara, Fatima Pagani, Cordoba, Marta, Gutierrez, Maria Teresa, Ingolotti, Mariana, Larripa, Natalia, Lupinacci, Anahi, Arroyo, Josefina, Romano, Alejandra, Torres, Mariana Foa, Ballario, Carlos Héctor, Chiesa, Ana Elisa, Gómez, Hernán Gustavo, Lattini, Hernán Gabriel, Mainella, Carolina Natalia, Bolner, Gisel Edith, Eschoyez, María Soledad, Broadley, Simon Andrew, Heshmat, Saman, Sabet, Arman, Swayne, Andrew, Freeman, Susan, Sanchez, Sofia Jimenez, Shuey, Neil, Dalic, Linda, French, Ann, Kuma, Guru, Laing, Joshua, Law, Lai Yin, MacIntyre, Jennifer, Neal, Andrew, Plummer, Christopher, Ramachandran, Prashanth, Sedal, Leslie, Wilson, Ian, Winkel, Antony, Zhang, Wenwen, Chen, Tina, Watts, Rani, Barnett, Michael, Barton, Joshua, Beadnall, Heidi, Garber, Justin, Hardy, Todd Andrew, Trewin, Benjamin, Taha, Marinda, Walters, Deleni, Sieger, Federico Arturo Silva, Alfonso, Nhora Patricia Ruiz, Camacho, Anna Maria Pinzon, Moreno, Alexander Pabón, Prad, Jorge Armando Castellanos, Rueda, Adriana Paola Duarte, Castillo, Tatiana, Gonzalez, Karol Melissa Castillo, Pico, Martha Yolanda Moreno, Castill, Judith, Habek, Mario, Adamec, Ivan, Barun, Barbara, Crnosija, Luka, Gabelic, Tereza, Nytrova, Petra, Krasulova, Eva, Pavlickova, Jana, Tyblova, Michaela, Zubkova, Jana, Petersen, Thor, Dale, Gro Helen, Rasmussen, Peter Vestergaard, Stilund, Morten, Svendsen, Kristina Bacher, Brandt, Vivi, Collongues, Nicolas, Fleury, Marie-Celine, Kremer, Laurent, Bendele, Sandrine, Neff, Valérie, Diem, Ricarda, Platten, Michael, Berberich, Anne, Jansen, Jonabelle, Jaschoneck, Hannah, Wildemann, Brigitte, Aures, Ursula, Brandenburger, Tanja, Haut, Tanja, Fernández, Maria-Lourdes Treceno, Aly, Lilian, Brinkhoff, Kirsten, Buck, Dorothea, Golkowski, Daniel, Hermisson, Mirjam, Hoshi, Muna-Miriam, Kaminski, Miriam, Kowarik, Markus Christian, Kronsbein, Helena, Lehmann-Horn, Klaus, Pongratz, Viola Maria, Schweiker, Andreas, Leddy, Lisa-Ann, Mueller, Silvia, Obergfell, Kim, Wanka, Marion, Zettl, Uwe Klaus, Klinke, Jan, Loebermann, Micha, Meister, Stefanie, Rimmele, Florian, Winkelmann, Alexander, Schroeder, Ina, Lau, Alexander Yuk-Lun, Au, Lisa Wing-Chi, Fan, Florence Sin-Ying, Ip, Vincent Hing-Lung, Ma, Karen Ka-Yan, Ma, Sze-Ho, Mok, Vincent Chung-Tong, Au, Cheryl Chung-Kwan, Kwan, Pauline Wing-Lam, Patti, Francesco, Caramma, Andrea Salvatore, Chisari, Clara Grazia, Fermo, Salvatore Lo, Messina, Silvia, Projetto, Maria, Caserta, Cinzia, Filla, Alessandro, Costabile, Teresa, Pane, Chiara, Sacca, Francesco, Marsili, Angela, Puorro, Giorgia, Bergamaschi, Roberto, Berra, Eliana, Mallucci, Giulia, Fattore, Cinzia, Gasperini, Claudio, Galgani, Simonetta, Haggiag, Shalom, Ruggieri, Serena, Vento, Claudio, Quartuccio, Esmeralda Maria, Pozzilli, Carlo, Barletta, Valeria Teresa, Borriello, Giovanna, De Giglio, Laura, Marinelli, Fabiana, Tasillo, Miriam, Amadori, Alessandra, Fischetti, Mariano, Gurreri, Flavia, Mori, Masahiro, Masuda, Hiroki, Ohtani, Ryohei, Sekiguchi, Yukari, Uchida, Tomohiko, Uzawa, Akiyuki, Ito, Hiromi, Kabasawa, Emi, Kaneko, Yoko, Matsushita, Takuya, Matsuse, Dai, Murai, Hiroyuki, Hayashi, Shintaro, Masak, Katsuhisa, Ogata, Hidenori, Shinoda, Koji, Uehara, Taira, Watanabe, Mitsuru, Yamaguchi, Hiroo, Yamasaki, Ryo, Yonekawa, Tomomi, Jingu, Maki, Nagano, Makiko, Nakamura, Yumiko, Sano, Yoshiko, Araki, Manabu, Lin, Youwei, Mori, Madoka, Mukai, Yohei, Sano, Terunori, Sato, Wakiro, Gogun, Naoya, Maeda, Yuriko, Nishimoto, Asami, Tsukamoto, Sachiko, Yanagi, Ritsuko, Saida, Takahiko, Nakamura, Shinichi, Nasu, Tetsuya, Saida, Kyoko, Shikata, Yuko, Kodani, Yoshimi, Saeki, Megumi, Sawada, Yukako, Yoshikawa, Hiroo, Kimura, Takashi, Nishi, Masamitsu, Sakamoto, Shun, Ukon, Shinichiro, Watanabe, Shohei, Ebisuya, Saori, Kimura, Nami, Matsuura, Manami, Morisaki, Yukie, Muroi, Yoshiko, Onishi, Kuniko, Oshima, Ikuko, Washino, Yuki, Yamashita, Tomomi, Misu, Tatsuro, Kaneko, Kimihiko, Kato, Masaaki, Kuroda, Hiroshi, Kurosawa, Kazuhiro, Nishiyama, Shuhei, Ono, Hirohiko, Takai, Yoshiki, Abe, Keiko, Hoshi, Hitomi, Jinushi, Mari, Oyama, Azusa, Sakuma, Motonari, Sawada, Yuko, Ishibashi, Satoru, Yokota, Takanori, Nishida, Yoichiro, Ozaki, Kokoro, Sanjo, Nobuo, Sato, Nozomu, Denno, Fuki, Hiraki, Haruko, Matsubara, Yumi, Kanda, Takashi, Abe, Masaaki, Honda, Masaya, Kawai, Motoharu, Koga, Michiaki, Maeda, Toshihiko, Ogasawara, Junichi, Omoto, Masatoshi, Sano, Yasuteru, Sato, Ryota, Shimizu, Fumitaka, Arima, Hideki, Fukui, Sachie, Ishikawa, Yoshiko, Koyama, Tomoko, Shimose, Shigemi, Shinozaki, Hirokazu, Watanabe, Masanori, Yasuda, Sachi, Yoshiwaka, Chieko, Adenan, Suffian, Aris, Mohd Azman M, Mawardi, Ahmad Shahir bin, Adnan, Muhammad Al Hafiz, Munusamy, Nanthini, Razali, Siti Nur Omaira, Somasundram, Punitha, Hyun, Jae Won, Jeong, In Hye, Kim, Su-Hyun, Shin, Hyun-June, Yoo, Ji Sung, Jang, HyunMin, Joung, AeRan, Kim, Byung-Jo, Baek, Seol-Hee, Kim, Jung Bin, Kim, Yoo Hwan, Koo, Yong Seo, Lee, Chan Nyoung, Seok, Hung Youl, Hwang, Jinhee, Kim, Sung Min, Ahn, So Hyun, Choi, Kyomin, Choi, Seok-Jin, Kim, Jun-Soon, Kwon, Young Nam, Shin, Je-Young, Kwon, Hyeonju, Kim, Byoung Joon, Cho, Eun Bin, Cho, Hye-Jin, Choi, Misong, Kim, DongSun, Kim, Ju Hyeon, Ki, SeungJu, Lee, Hye Lim, Lee, Kwang-Ho, Min, Ju-Hong, Park, Ji-Hyung, Seok, Jinmyoung, Choi, Eunhwa, Park, Sang Ae, Kim, Seung Min, Jeong, Ha-Neul, Jeongbin, Bong, Jung, Jin Woo, Kim, Seung Woo, Kim, Yool-hee, Lee, Hyung Seok, Shin, Ha Young, Jung, Yeon, Kim, Min Jung, Lee, Nou Ri, Shin, MiJu, Khabirov, Farit A, Averyanova, Lyudmila, Babicheva, Natalya, Granatov, Eugenii, Kazarov, Sergey, Khaybullin, Timur, Rogozhin, Alexander, Pokhabov, Dmitry V, Abramov, Vladislav, Amelina, Anastasia, Nesteroca, Yulia, Bozhenkina, Tatyana, Boyko, Aleksey N, Demyan, Elena G, Khoroshilova, Inessa, Melnikov, Mikhail, Popova, Ekaterina V, Sharanova, Svetlana N, Shchur, Sergey G, Sazonov, Denis V, Babenko, Larisa, Bayandina, Elena, Yarmoschuk, Asya, Baliazin, Victor A, Baliazina, Elena, Budaeva, Elena, Chernikova, Irina, Goncharova, Zoya, Krasnov, Vladimir, Myatleva, Marina, Rodionova, Olga V., Samulyzhko, Iuliana, Timofeeva, Alla A., Duran, Sabas Boyero, Bilbao, Maria Mar Mendibe, Cuervo, Irene Diaz, Domingo, Jose Maria Losada, Eizaguirre, Amaia Gonzalez, Llona, Jose Eulalio Barcena, Moyano, Roberto Valverde, Bahamonde, Carmen, Lopez, Fernando Sanchez, Morales, Raquel Pinar, Morales, Eduardo Agüera, Roman, Carmen Bahamonde, Sepulveda, Juan Jose Ochoa, Valero, Maria del Carmen Blanco, Viña, Nazaret Pelaez, Gavilan, Cristina Conde, Sanchez, Ana Maria Jover, Bedmar, Sara Vila, Garcia, Nuria Gonzalez, Garcia, Aida Orviz, Gonzalez-Suarez, Ines, Guillamon, Elena Miñano, Kawiorski, Miguel, Schulz, Elena Guerra, Alonso, Alba Garcia, Perez, Francisco Jesus Lopez, Sarmiento, Marta Palacios, Ayuso, Guillermo Izquierdo, Mascarell, Guillermo Navarro, Camino, Cristina Paramo, Garcia, Asuncion Varas, Mendoza, Yaiza Montserrat, Muñoz, Veronica Ines Vargas, Tonda, Patricia Torres, Tsai, Ching-Piao, Yin, Jiu-Haw, Chen, Mei-Jung, Li, Shan-Ni, Wang, Fei-Ti, Srisuwannanukorn, Suwat, Boonmongkol, Thanatat, Borisutbuathip, Duangporn, Singwicha, Duangkamol, Siritanan, Krittika, Thearapati, Chidchanoke, Sornda, Kwanmuang, Apiwattanakul, Metha, Aungsumart, Saharat, Suanprasert, Narupat, Suksuchano, Kaona, Parkinsee, Nittaya, Kulkantrakorn, Kongkiat, Lolekha, Praween, Potigumjon, Artit, Sukphulloprat, Puchit, Suksasunee, Dararat, Komaratat, Chankawee, Luangtong, Sunattana, Arayawichanont, Arkhom, Konpan, Phanpaphon, Riablershirun, Nathapol, Wiroteurairuang, Thaddao, Jantaweesirirat, Panadda, Kurne, Aslı, Erkent, Irem, Kurt, Ebru Bekircan, Saylam, Ezgi, Caliskan, Yagmur, Orsel, Gulsah, Celik, Yahya, Celebi, Canan, Tekatas, Aslan, Banbal, Tugce, Demir, Gulsen Akman, Altunrende, Burcu, Matur, Zeliha, Topcular, Baris, Elmas, Tules, Gulo, Aysenur, Ozdemir, Selin, Ozkoklesen, Cansu, Ozturk, Mahinur, Yanik, Mertkan, Yildirim, Elif, Tutuncu, Melih, Altintas, Ayse, Cam, Abdulsamet, Elmali, Ayse Deniz, Saip, Sabahattin, Siva, Aksel, Tanrıverdi, Uygur, Uygunoglu, Ugur, Caliskan, Sinem, Gulo, Pinar, Kozig, Esra, Sakiz, Sakine, Sengun, Ihsan Sukru, Idiman, Egemen, Ala, Rahmi Tumay, Arslan, Duygu, Bulut, Utku, Karakaptan, Yasemin, Kaya, Derya, Mehdiyev, Zaur, Balkan, Bengu, Kuku, Berfu, Ozhun, Mujgan, Tuga, Celal, Ugur, Muzeyyen, Efendi, Husnu, Bunul, Sena Destan, Cavus, Hakan, Gorke, Yunus Emre, Kutlu, Ayse, Ozturk, Seda, Sarikaya, Cansu Egilmez, Becerikli, Gulsah, Semiz, Cansu, Tun, Ozlem, Ayer, Sehriban, Onar, Musa Kazim, Ozberk, Mehlika Berra, Sen, Sedat, Cavdar, Tugce Kirbas, Veske, Adife, Boz, Cavit, Altiparmak, Didem, Aydin, Cigdem Ozen, Gazioglu, Sibel, Bekircan, Duygu, Jacob, Anu, Arndt, Heike, Elsone, Liene, Hamid, Shahd Hassan Mahmoud, Whittam, Daniel Hugh, Wilson, Martin, O'Brien, Imelda, Leite, Maria Isabel da Silva, Cruz, Pedro Maria Rodriguez, Jenkins, Damian Robert, Tackley, George, Cavey, Ana, Everett, Rosie, Hodder, Joy, Koelewyn, Abigail, Mowry, Ellen, Royal, Walter, III, Shin, Robert, Bever, Christopher, Jr, Harrison, Daniel, Rus, Horea, Zheng, Wei, Callison, Karen, Naunton, Kerry, Frishberg, Benjamin M, Blumenfeld, Andrew M, Inocelda, Andrew, Korabathina, Kalyani, Lobatz, Michael, Mortin, Melissa M, Oh, Irene J, Rosenberg, Jay H, Sadoff, Mark, Sahagian, Gregory A, Wang, Anchi, Camberos, Yasmin, Sanchez, Guadalupe, Soto, Estela, Nicholas, Jacqueline A, Boster, Aaron, Eubank, Geoffrey, Groezinger, Katy, Lauf, Meghan, Okai, Annette F, Hasan, Rashedul, Khoury, Chaouki, Stokes, Victoria, Clardy, Stacey, Cortez, Melissa, Greenlee, John, Rose, John, Soldan, Mateo Paz, Emett, Amanda, Esquibel, Lawanda, Fagatele, Lilly, Wong, Ka-Ho, Stevens, James C, Banas, Thomas M, Bultemeyer, Marlene C, Haller, Andrea, Manalo, Natalie, Aeschliman, Keri, Kocks, Debi, Racke, Michael, Boster, Aaron Lee, Bowman, Michelle, Imitola, Jaime, Kisanuki, Yasushi, Green, Misty, Scarberry, Stephanie, Lynch, Sharon G, Anderson, Heather S, Gronseth, Gary S, Hammond, Nancy E, Jassam, Yasir N, Mittal, Manoj K, Nashatizadeh, Muhammed M, Levine, Nicholas, Schmidt, Lisa, Sibley, Jill, Whitley, Vonda, Winkley, James, Coleman, Timothy, Cooper, Gregory, Sheffield, Stephanie, Turner, Keri, Galloway, Dana, Tillett, Robert S, Jr, Ganesh, Geeta A, Plato, Brian M, Seifert, Tad D, Godwin, Diana, Lockridge, Deborah, Rammohan, Kottil W, Sheremata, William A, Delgado, Silvia, Gonzalez, Jose, Lizarraga, Alexis, Maldonado, Janice, Ortega, Melissa, Tornes, Leticia, Babcock, Yanet, Cailam, Osmara, Campos, Yesica, Couvertier, Irlisse, Daneri, Bettina, Deni, Jeremy, Hernandez, Jeffrey, Jaramillo, Tatiana, Morris, Tenita, Nobel, Daniel, Oliveira, Anjelis, Richardson, Reshma, Rodriguez, Gloria, Romero, Ana, Sandova, Carlos, Sawant, Ruta, Tueros, Lissett, Zetka, Eric S, Zheng, Chao, Jacobs, Daniel H, Easterling, Constance, Fairbank, Jennifer, Iyengar, Revathi, Klafter, Mark, Lindquist, Justin, Sadek, Ahmed H, Toro, Elizabeth Carmona, Verma, Navin, Castro, Brigith Patino, Sukhraj-Singh, Nadia, Berger, Joseph, Williamson, Eric, Chahin, Salim, Jacobs, Dina, Markowitz, Clyde, Dobbins, Jessica, Mace, Lauren, Martin, Maria, Pinckney, Ashley, Roberts, Amber, Zaydan, Islam, Mitchell, Galen W, Heyman, Rock A, Orie, Ryan L, Suski, Valerie R, Oddis, Kerry, Punjack, Darlene, Flanagan, Eoin, Gadoth, Avi, McKeon, Andrew, Tobin, W Oliver, Zekeridou, Anastasia, Dunlay, Katie, Sagen, Jessica, Carter, Jonathan L, Estephan, Bachir, Goodman, Brent P, Snyder, Charlene R Hoffman, Francone, Andrea, Galasky, Irene, Thomas, Martha, Repovic, Pavle, Bowen, James, Mayadev, Angeli, Qian, Peiqing, Courtney, Yuriko, Lennox, Lauren, Naismith, Robert Thomas, Cross, Anne Haney, Evans, Emily, Longbrake, Erin E, Orchard, Megan E, Wu, Gregory F, Heinrich, Linda, Sommers, Susan, Amjad, Faria, Mitchell, Erika, Mora, Carlos, Schreiber, Bethany, Tornatore, Carlo, Carlson, Alexis, McCarthy, Sacha, Oliver, Alexandria, Palace, Jacqueline, Wingerchuk, Dean M., Fujihara, Kazuo, Berthele, Achim, Oreja-Guevara, Celia, Kim, Ho Jin, Nakashima, Ichiro, Levy, Michael, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Pace, Amy, Yountz, Marcus, Miller, Larisa, Armstrong, Róisín, and Pittock, Sean

Published
2021
Full Text
View/download PDF

8. COVID-19 vaccination and relapse activity:A nationwide cohort study of patients with multiple sclerosis in Denmark

Author

Stastna, Dominika, Elberling, Frederik, Pontieri, Luigi, Framke, Elisabeth, Horakova, Dana, Drahota, Jiri, Nytrova, Petra, Magyari, Melinda, Stastna, Dominika, Elberling, Frederik, Pontieri, Luigi, Framke, Elisabeth, Horakova, Dana, Drahota, Jiri, Nytrova, Petra, and Magyari, Melinda

Abstract

Background and purpose We evaluated whether there was a difference in the occurrence of relapses pre- and post-COVID-19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis. Methods We conducted a population-based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors. Results We identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID-19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre- and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058–0.070) with the ARR 90 (0.057, 95% CI = 0.047–0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048–0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse. Conclusions We did not find evidence of increased relapse activity following the administration of the first dose of the COVID-19 vaccine., Background and purpose: We evaluated whether there was a difference in the occurrence of relapses pre- and post-COVID-19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis. Methods: We conducted a population-based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors. Results: We identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID-19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre- and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058–0.070) with the ARR 90 (0.057, 95% CI = 0.047–0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048–0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse. Conclusions: We did not find evidence of increased relapse activity following the administration of the first dose of the COVID-19 vaccine.

Published
2024

9. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

Author

Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva Kubala, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga, Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse, Soysal, Aysun, Vucic, Steve, Grand'Maison, Francois, Izquierdo, Guillermo, Eichau, Sara, Lugaresi, Alessandra, Onofrj, Marco, Trojano, Maria, Marriott, Mark, Butzkueven, Helmut, Kister, Ilya, and Kalincik, Tomas

Published
2020
Full Text
View/download PDF

11. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

Author

Jensen, Poul Erik H., Warnke, Clemens, Ingenhoven, Kathleen, Piccoli, Luca, Gasis, Marcia, Hermanrud, Christina, Fernandez-Rodriguez, Blanca M., Ryner, Malin, Kramer, Daniel, Link, Jenny, Ramanujam, Ryan, Auer, Michael, Buck, Dorothea, Grummel, Verena, Bertotti, Elisa, Fissolo, Nicolas, Oliver-Martos, Begoña, Nytrova, Petra, Khalil, Michael, Guger, Michael, Rathmaier, Sandra, Sievers-Stober, Claudia, Lindberg, Raija L.P., Hässler, Signe, Bachelet, Delphine, Aktas, Orhan, Donnellan, Naoimh, Lawton, Andy, Hemmer, Bernhard, Havrdova, Eva Kubala, Kieseier, Bernd, Hartung, Hans-Peter, Comabella, Manuel, Montalban, Xavier, Derfuss, Tobias, Sellebjerg, Finn, Dönnes, Pierre, Pallardy, Marc, Spindeldreher, Sebastian, Broët, Philippe, Deisenhammer, Florian, Fogdell-Hahn, Anna, and Sorensen, Per Soelberg

Published
2019
Full Text
View/download PDF

13. Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis

Author

Ravano, Veronica, primary, Piredda, Gian Franco, additional, Krasensky, Jan, additional, Andelova, Michaela, additional, Uher, Tomas, additional, Srpova, Barbora, additional, Havrdova, Eva Kubala, additional, Vodehnalova, Karolina, additional, Horakova, Dana, additional, Nytrova, Petra, additional, Disselhorst, Jonathan A., additional, Hilbert, Tom, additional, Maréchal, Bénédicte, additional, Thiran, Jean-Philippe, additional, Kober, Tobias, additional, Richiardi, Jonas, additional, and Vaneckova, Manuela, additional

Published
2023
Full Text
View/download PDF

14. COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark.

Author

Stastna, Dominika, Elberling, Frederik, Pontieri, Luigi, Framke, Elisabeth, Horakova, Dana, Drahota, Jiri, Nytrova, Petra, and Magyari, Melinda

Subjects
COVID-19 vaccines, MULTIPLE sclerosis, COHORT analysis, DISEASE relapse, DANES
Abstract

Background and purpose: We evaluated whether there was a difference in the occurrence of relapses pre‐ and post‐COVID‐19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis. Methods: We conducted a population‐based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors. Results: We identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID‐19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre‐ and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058–0.070) with the ARR 90 (0.057, 95% CI = 0.047–0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048–0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse. Conclusions: We did not find evidence of increased relapse activity following the administration of the first dose of the COVID‐19 vaccine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

Author

Nytrova, Petra, primary, Stastna, Dominika, additional, Tesar, Adam, additional, Menkyova, Ingrid, additional, Posova, Helena, additional, Koprivova, Helena, additional, Mikulova, Veronika, additional, Hrdy, Jiri, additional, Smela, Gabriela, additional, Horakova, Dana, additional, Rysankova, Irena, additional, Doleckova, Kristyna, additional, and Tyblova, Michaela, additional

Published
2023
Full Text
View/download PDF

16. Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014]

Author

Stastna, Dominika, primary, Menkyova, Ingrid, additional, Drahota, Jiri, additional, Hrnciarova, Tereza, additional, Kubala Havrdova, Eva, additional, Vachova, Marta, additional, Andelova, Michaela, additional, Kleinova, Pavlina, additional, Kovarova, Ivana, additional, Krasulova, Eva, additional, Lizrova Preiningerova, Jana, additional, Novakova, Iveta, additional, Novotna, Klara, additional, Novotna, Martina, additional, Nytrova, Petra, additional, Pavlickova, Jana, additional, Srpova, Barbora, additional, Storey, Katerina, additional, Ticha, Veronika, additional, Tyblova, Michaela, additional, Uher, Tomas, additional, Vodehnalova, Karolina, additional, and Horakova, Dana, additional

Published
2023
Full Text
View/download PDF

17. Relapsing Remitting and Secondary Progressive Multiple Sclerosis are Characterised by Distinct Metabolomic and Transcriptomic Signatures That Could Aid Patient Management Strategies

Author

Oppong, Alexandra E., primary, Coelewij, Leda, additional, Robertson, Georgia, additional, Martin-Gutierrez, Lucia, additional, Waddington, Kirsty E., additional, Dönnes, Pierre, additional, Nytrova, Petra, additional, Farrell, Rachel, additional, Pineda-Torra, Inés, additional, and Jury, Elizabeth C., additional

Published
2023
Full Text
View/download PDF

18. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

Author

Hässler, Signe, Bachelet, Delphine, Duhaze, Julianne, Szely, Natacha, Gleizes, Aude, Hacein-Bey Abina, Salima, Aktas, Orhan, Auer, Michael, Avouac, Jerôme, Birchler, Mary, Bouhnik, Yoram, Brocq, Olivier, Buck-Martin, Dorothea, Cadiot, Guillaume, Carbonnel, Franck, Chowers, Yehuda, Comabella, Manuel, Derfuss, Tobias, De Vries, Niek, Donnellan, Naoimh, Doukani, Abiba, Guger, Michael, Hartung, Hans-Peter, Kubala Havrdova, Eva, Hemmer, Bernhard, Huizinga, Tom, Ingenhoven, Kathleen, Hyldgaard-Jensen, Poul Erik, Jury, Elizabeth C., Khalil, Michael, Kieseier, Bernd, Laurén, Anna, Lindberg, Raija, Loercher, Amy, Maggi, Enrico, Manson, Jessica, Mauri, Claudia, Mohand Oumoussa, Badreddine, Montalban, Xavier, Nachury, Maria, Nytrova, Petra, Richez, Christophe, Ryner, Malin, Sellebjerg, Finn, Sievers, Claudia, Sikkema, Dan, Soubrier, Martin, Tourdot, Sophie, Trang, Caroline, Vultaggio, Alessandra, Warnke, Clemens, Spindeldreher, Sebastian, Dönnes, Pierre, Hickling, Timothy P., Hincelin Mery, Agnès, Allez, Matthieu, Deisenhammer, Florian, Fogdell-Hahn, Anna, Mariette, Xavier, Pallardy, Marc, and Broët, Philippe

Subjects
Autoimmune diseases -- Drug therapy -- Genetic aspects, Biopharmaceuticals -- Usage -- Complications and side effects, Immune response -- Genetic aspects -- Health aspects, Biological sciences
Abstract

Background Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug antibodies (ADAs) is still limited. Methods and findings The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK) conducted a clinical and genomic multicohort prospective study of 560 patients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 months of therapy for time to ADA development. From the bioclinical data collected, we explored the relationships between patient-related factors and the occurrence of ADAs. Both baseline and time-dependent factors such as concomitant medications were analyzed using Cox proportional hazard regression models. Mean age and disease duration were 35.1 and 0.85 years, respectively, for MS; 54.2 and 3.17 years for RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs). In a multivariate Cox regression model including each of the clinical and genetic factors mentioned hereafter, among the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408 [95% confidence interval (CI) 0.253-0.657], p < 0.001) and antibiotics (aHR = 0.121 [0.0437-0.333], p < 0.0001) were independently negatively associated with time to ADA development, whereas infections during the study (aHR = 2.757 [1.616-4.704], p < 0.001) and tobacco smoking (aHR = 2.150 [1.319-3.503], p < 0.01) were positively associated. 351,824 Single-Nucleotide Polymorphisms (SNPs) and 38 imputed Human Leukocyte Antigen (HLA) alleles were analyzed through a genome-wide association study. We found that the HLA-DQA1*05 allele significantly increased the rate of immunogenicity (aHR = 3.9 [1.923-5.976], p < 0.0001 for the homozygotes). Among the 6 genetic variants selected at a 20% false discovery rate (FDR) threshold, the minor allele of rs10508884, which is situated in an intron of the CXCL12 gene, increased the rate of immunogenicity (aHR = 3.804 [2.139-6.764], p < 1 x 10.sup.-5 for patients homozygous for the minor allele) and was chosen for validation through a CXCL12 protein enzyme-linked immunosorbent assay (ELISA) on patient serum at baseline before therapy start. CXCL12 protein levels were higher for patients homozygous for the minor allele carrying higher ADA risk (mean: 2,693 pg/ml) than for the other genotypes (mean: 2,317 pg/ml; p = 0.014), and patients with CXCL12 levels above the median in serum were more prone to develop ADAs (aHR = 2.329 [1.106-4.90], p = 0.026). A limitation of the study is the lack of replication; therefore, other studies are required to confirm our findings. Conclusion In our study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA development, whereas tobacco smoking and infections during the study were associated with increased risk. We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a relationship between CXCL12 production and ADA development independent of the disease, which is consistent with its known function in affinity maturation of antibodies and plasma cell survival. Our findings may help physicians in the management of patients receiving biotherapies., Author(s): Signe Hässler 1,2,3,*, Delphine Bachelet 1,4, Julianne Duhaze 1,5, Natacha Szely 6, Aude Gleizes 6,7, Salima Hacein-Bey Abina 7,8, Orhan Aktas 9, Michael Auer 10, Jerôme Avouac 11,12, Mary [...]

Published
2020
Full Text
View/download PDF

23. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease:A prospective multicohort study of the ABIRISK consortium

Author

Hässler, Signe, Bachelet, Delphine, Duhaze, Julianne, Szely, Natacha, Gleizes, Aude, Hacein-Bey Abina, Salima, Aktas, Orhan, Auer, Michael, Avouac, Jerôme, Birchler, Mary, Bouhnik, Yoram, Brocq, Olivier, Buck-Martin, Dorothea, Cadiot, Guillaume, Carbonnel, Franck, Chowers, Yehuda, Comabella, Manuel, Derfuss, Tobias, De Vries, Niek, Donnellan, Naoimh, Doukani, Abiba, Guger, Michael, Hartung, Hans-Peter, Kubala Havrdova, Eva, Hemmer, Bernhard, Huizinga, Tom, Ingenhoven, Kathleen, Hyldgaard-Jensen, Poul Erik, Jury, Elizabeth C, Khalil, Michael, Kieseier, Bernd, Laurén, Anna, Lindberg, Raija, Loercher, Amy, Maggi, Enrico, Manson, Jessica, Mauri, Claudia, Mohand Oumoussa, Badreddine, Montalban, Xavier, Nachury, Maria, Nytrova, Petra, Richez, Christophe, Ryner, Malin, Sellebjerg, Finn, Sievers, Claudia, Sikkema, Dan, Soubrier, Martin, Tourdot, Sophie, Trang, Caroline, Vultaggio, Alessandra, Hässler, Signe, Bachelet, Delphine, Duhaze, Julianne, Szely, Natacha, Gleizes, Aude, Hacein-Bey Abina, Salima, Aktas, Orhan, Auer, Michael, Avouac, Jerôme, Birchler, Mary, Bouhnik, Yoram, Brocq, Olivier, Buck-Martin, Dorothea, Cadiot, Guillaume, Carbonnel, Franck, Chowers, Yehuda, Comabella, Manuel, Derfuss, Tobias, De Vries, Niek, Donnellan, Naoimh, Doukani, Abiba, Guger, Michael, Hartung, Hans-Peter, Kubala Havrdova, Eva, Hemmer, Bernhard, Huizinga, Tom, Ingenhoven, Kathleen, Hyldgaard-Jensen, Poul Erik, Jury, Elizabeth C, Khalil, Michael, Kieseier, Bernd, Laurén, Anna, Lindberg, Raija, Loercher, Amy, Maggi, Enrico, Manson, Jessica, Mauri, Claudia, Mohand Oumoussa, Badreddine, Montalban, Xavier, Nachury, Maria, Nytrova, Petra, Richez, Christophe, Ryner, Malin, Sellebjerg, Finn, Sievers, Claudia, Sikkema, Dan, Soubrier, Martin, Tourdot, Sophie, Trang, Caroline, and Vultaggio, Alessandra

Abstract

BACKGROUND: Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug antibodies (ADAs) is still limited.METHODS AND FINDINGS: The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK) conducted a clinical and genomic multicohort prospective study of 560 patients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 months of therapy for time to ADA development. From the bioclinical data collected, we explored the relationships between patient-related factors and the occurrence of ADAs. Both baseline and time-dependent factors such as concomitant medications were analyzed using Cox proportional hazard regression models. Mean age and disease duration were 35.1 and 0.85 years, respectively, for MS; 54.2 and 3.17 years for RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs). In a multivariate Cox regression model including each of the clinical and genetic factors mentioned hereafter, among the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408 [95% confidence interval (CI) 0.253-0.657], p < 0.001) and antibiotics (aHR = 0.121 [0.0437-0.333], p < 0.0001) were independently negatively associated with time to ADA development, whereas infections during the study (aHR = 2.757 [1.616-4.704], p < 0.001) and tobacco smoking (aHR = 2.150 [1.319-3.503], p < 0.01) were positively associated.

Published
2020

24. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Author

Palace, Jacqueline, primary, Wingerchuk, Dean M., additional, Fujihara, Kazuo, additional, Berthele, Achim, additional, Oreja-Guevara, Celia, additional, Kim, Ho Jin, additional, Nakashima, Ichiro, additional, Levy, Michael, additional, Terzi, Murat, additional, Totolyan, Natalia, additional, Viswanathan, Shanthi, additional, Wang, Kai-Chen, additional, Pace, Amy, additional, Yountz, Marcus, additional, Miller, Larisa, additional, Armstrong, Róisín, additional, Pittock, Sean, additional, Muñoz, Daniel Julio, additional, Amor, Jorge David, additional, Bocchiardo, Carolina, additional, Danielle, Julieta Iourno, additional, Laffue, Alfredo, additional, Obregon, Carolina Daniela Diaz, additional, Paez, Maria Fernanda, additional, Perez, Roberto Martin, additional, Rocchi, Viviana Ana Maria, additional, Teijeiro, Loreley Deborah, additional, Gómez, Jesica, additional, Villa, Andres Maria, additional, Aguirre, Florencia, additional, Fernández, Victoria Carla, additional, Goicoechea, Ramon F., additional, Melamud, Luciana, additional, Stillman, Ana, additional, de Virgiliis, Mariana, additional, Cassara, Fatima Pagani, additional, Cordoba, Marta, additional, Gutierrez, Maria Teresa, additional, Ingolotti, Mariana, additional, Larripa, Natalia, additional, Lupinacci, Anahi, additional, Arroyo, Josefina, additional, Romano, Alejandra, additional, Torres, Mariana Foa, additional, Ballario, Carlos Héctor, additional, Chiesa, Ana Elisa, additional, Gómez, Hernán Gustavo, additional, Lattini, Hernán Gabriel, additional, Mainella, Carolina Natalia, additional, Bolner, Gisel Edith, additional, Eschoyez, María Soledad, additional, Broadley, Simon Andrew, additional, Heshmat, Saman, additional, Sabet, Arman, additional, Swayne, Andrew, additional, Freeman, Susan, additional, Sanchez, Sofia Jimenez, additional, Shuey, Neil, additional, Dalic, Linda, additional, French, Ann, additional, Kuma, Guru, additional, Laing, Joshua, additional, Law, Lai Yin, additional, MacIntyre, Jennifer, additional, Neal, Andrew, additional, Plummer, Christopher, additional, Ramachandran, Prashanth, additional, Sedal, Leslie, additional, Wilson, Ian, additional, Winkel, Antony, additional, Zhang, Wenwen, additional, Chen, Tina, additional, Watts, Rani, additional, Barnett, Michael, additional, Barton, Joshua, additional, Beadnall, Heidi, additional, Garber, Justin, additional, Hardy, Todd Andrew, additional, Trewin, Benjamin, additional, Taha, Marinda, additional, Walters, Deleni, additional, Sieger, Federico Arturo Silva, additional, Alfonso, Nhora Patricia Ruiz, additional, Camacho, Anna Maria Pinzon, additional, Moreno, Alexander Pabón, additional, Prad, Jorge Armando Castellanos, additional, Rueda, Adriana Paola Duarte, additional, Castillo, Tatiana, additional, Gonzalez, Karol Melissa Castillo, additional, Pico, Martha Yolanda Moreno, additional, Castill, Judith, additional, Habek, Mario, additional, Adamec, Ivan, additional, Barun, Barbara, additional, Crnosija, Luka, additional, Gabelic, Tereza, additional, Nytrova, Petra, additional, Krasulova, Eva, additional, Pavlickova, Jana, additional, Tyblova, Michaela, additional, Zubkova, Jana, additional, Petersen, Thor, additional, Dale, Gro Helen, additional, Rasmussen, Peter Vestergaard, additional, Stilund, Morten, additional, Svendsen, Kristina Bacher, additional, Brandt, Vivi, additional, Collongues, Nicolas, additional, Fleury, Marie-Celine, additional, Kremer, Laurent, additional, Bendele, Sandrine, additional, Neff, Valérie, additional, Diem, Ricarda, additional, Platten, Michael, additional, Berberich, Anne, additional, Jansen, Jonabelle, additional, Jaschoneck, Hannah, additional, Wildemann, Brigitte, additional, Aures, Ursula, additional, Brandenburger, Tanja, additional, Haut, Tanja, additional, Fernández, Maria-Lourdes Treceno, additional, Aly, Lilian, additional, Brinkhoff, Kirsten, additional, Buck, Dorothea, additional, Golkowski, Daniel, additional, Hermisson, Mirjam, additional, Hoshi, Muna-Miriam, additional, Kaminski, Miriam, additional, Kowarik, Markus Christian, additional, Kronsbein, Helena, additional, Lehmann-Horn, Klaus, additional, Pongratz, Viola Maria, additional, Schweiker, Andreas, additional, Leddy, Lisa-Ann, additional, Mueller, Silvia, additional, Obergfell, Kim, additional, Wanka, Marion, additional, Zettl, Uwe Klaus, additional, Klinke, Jan, additional, Loebermann, Micha, additional, Meister, Stefanie, additional, Rimmele, Florian, additional, Winkelmann, Alexander, additional, Schroeder, Ina, additional, Lau, Alexander Yuk-Lun, additional, Au, Lisa Wing-Chi, additional, Fan, Florence Sin-Ying, additional, Ip, Vincent Hing-Lung, additional, Ma, Karen Ka-Yan, additional, Ma, Sze-Ho, additional, Mok, Vincent Chung-Tong, additional, Au, Cheryl Chung-Kwan, additional, Kwan, Pauline Wing-Lam, additional, Patti, Francesco, additional, Caramma, Andrea Salvatore, additional, Chisari, Clara Grazia, additional, Fermo, Salvatore Lo, additional, Messina, Silvia, additional, Projetto, Maria, additional, Caserta, Cinzia, additional, Filla, Alessandro, additional, Costabile, Teresa, additional, Pane, Chiara, additional, Sacca, Francesco, additional, Marsili, Angela, additional, Puorro, Giorgia, additional, Bergamaschi, Roberto, additional, Berra, Eliana, additional, Mallucci, Giulia, additional, Fattore, Cinzia, additional, Gasperini, Claudio, additional, Galgani, Simonetta, additional, Haggiag, Shalom, additional, Ruggieri, Serena, additional, Vento, Claudio, additional, Quartuccio, Esmeralda Maria, additional, Pozzilli, Carlo, additional, Barletta, Valeria Teresa, additional, Borriello, Giovanna, additional, De Giglio, Laura, additional, Marinelli, Fabiana, additional, Tasillo, Miriam, additional, Amadori, Alessandra, additional, Fischetti, Mariano, additional, Gurreri, Flavia, additional, Mori, Masahiro, additional, Masuda, Hiroki, additional, Ohtani, Ryohei, additional, Sekiguchi, Yukari, additional, Uchida, Tomohiko, additional, Uzawa, Akiyuki, additional, Ito, Hiromi, additional, Kabasawa, Emi, additional, Kaneko, Yoko, additional, Matsushita, Takuya, additional, Matsuse, Dai, additional, Murai, Hiroyuki, additional, Hayashi, Shintaro, additional, Masak, Katsuhisa, additional, Ogata, Hidenori, additional, Shinoda, Koji, additional, Uehara, Taira, additional, Watanabe, Mitsuru, additional, Yamaguchi, Hiroo, additional, Yamasaki, Ryo, additional, Yonekawa, Tomomi, additional, Jingu, Maki, additional, Nagano, Makiko, additional, Nakamura, Yumiko, additional, Sano, Yoshiko, additional, Araki, Manabu, additional, Lin, Youwei, additional, Mori, Madoka, additional, Mukai, Yohei, additional, Sano, Terunori, additional, Sato, Wakiro, additional, Gogun, Naoya, additional, Maeda, Yuriko, additional, Nishimoto, Asami, additional, Tsukamoto, Sachiko, additional, Yanagi, Ritsuko, additional, Saida, Takahiko, additional, Nakamura, Shinichi, additional, Nasu, Tetsuya, additional, Saida, Kyoko, additional, Shikata, Yuko, additional, Kodani, Yoshimi, additional, Saeki, Megumi, additional, Sawada, Yukako, additional, Yoshikawa, Hiroo, additional, Kimura, Takashi, additional, Nishi, Masamitsu, additional, Sakamoto, Shun, additional, Ukon, Shinichiro, additional, Watanabe, Shohei, additional, Ebisuya, Saori, additional, Kimura, Nami, additional, Matsuura, Manami, additional, Morisaki, Yukie, additional, Muroi, Yoshiko, additional, Onishi, Kuniko, additional, Oshima, Ikuko, additional, Washino, Yuki, additional, Yamashita, Tomomi, additional, Misu, Tatsuro, additional, Kaneko, Kimihiko, additional, Kato, Masaaki, additional, Kuroda, Hiroshi, additional, Kurosawa, Kazuhiro, additional, Nishiyama, Shuhei, additional, Ono, Hirohiko, additional, Takai, Yoshiki, additional, Abe, Keiko, additional, Hoshi, Hitomi, additional, Jinushi, Mari, additional, Oyama, Azusa, additional, Sakuma, Motonari, additional, Sawada, Yuko, additional, Ishibashi, Satoru, additional, Yokota, Takanori, additional, Nishida, Yoichiro, additional, Ozaki, Kokoro, additional, Sanjo, Nobuo, additional, Sato, Nozomu, additional, Denno, Fuki, additional, Hiraki, Haruko, additional, Matsubara, Yumi, additional, Kanda, Takashi, additional, Abe, Masaaki, additional, Honda, Masaya, additional, Kawai, Motoharu, additional, Koga, Michiaki, additional, Maeda, Toshihiko, additional, Ogasawara, Junichi, additional, Omoto, Masatoshi, additional, Sano, Yasuteru, additional, Sato, Ryota, additional, Shimizu, Fumitaka, additional, Arima, Hideki, additional, Fukui, Sachie, additional, Ishikawa, Yoshiko, additional, Koyama, Tomoko, additional, Shimose, Shigemi, additional, Shinozaki, Hirokazu, additional, Watanabe, Masanori, additional, Yasuda, Sachi, additional, Yoshiwaka, Chieko, additional, Adenan, Suffian, additional, Aris, Mohd Azman M, additional, Mawardi, Ahmad Shahir bin, additional, Adnan, Muhammad Al Hafiz, additional, Munusamy, Nanthini, additional, Razali, Siti Nur Omaira, additional, Somasundram, Punitha, additional, Hyun, Jae Won, additional, Jeong, In Hye, additional, Kim, Su-Hyun, additional, Shin, Hyun-June, additional, Yoo, Ji Sung, additional, Jang, HyunMin, additional, Joung, AeRan, additional, Kim, Byung-Jo, additional, Baek, Seol-Hee, additional, Kim, Jung Bin, additional, Kim, Yoo Hwan, additional, Koo, Yong Seo, additional, Lee, Chan Nyoung, additional, Seok, Hung Youl, additional, Hwang, Jinhee, additional, Kim, Sung Min, additional, Ahn, So Hyun, additional, Choi, Kyomin, additional, Choi, Seok-Jin, additional, Kim, Jun-Soon, additional, Kwon, Young Nam, additional, Shin, Je-Young, additional, Kwon, Hyeonju, additional, Kim, Byoung Joon, additional, Cho, Eun Bin, additional, Cho, Hye-Jin, additional, Choi, Misong, additional, Kim, DongSun, additional, Kim, Ju Hyeon, additional, Ki, SeungJu, additional, Lee, Hye Lim, additional, Lee, Kwang-Ho, additional, Min, Ju-Hong, additional, Park, Ji-Hyung, additional, Seok, Jinmyoung, additional, Choi, Eunhwa, additional, Park, Sang Ae, additional, Kim, Seung Min, additional, Jeong, Ha-Neul, additional, Jeongbin, Bong, additional, Jung, Jin Woo, additional, Kim, Seung Woo, additional, Kim, Yool-hee, additional, Lee, Hyung Seok, additional, Shin, Ha Young, additional, Jung, Yeon, additional, Kim, Min Jung, additional, Lee, Nou Ri, additional, Shin, MiJu, additional, Khabirov, Farit A, additional, Averyanova, Lyudmila, additional, Babicheva, Natalya, additional, Granatov, Eugenii, additional, Kazarov, Sergey, additional, Khaybullin, Timur, additional, Rogozhin, Alexander, additional, Pokhabov, Dmitry V, additional, Abramov, Vladislav, additional, Amelina, Anastasia, additional, Nesteroca, Yulia, additional, Bozhenkina, Tatyana, additional, Boyko, Aleksey N, additional, Demyan, Elena G, additional, Khoroshilova, Inessa, additional, Melnikov, Mikhail, additional, Popova, Ekaterina V, additional, Sharanova, Svetlana N, additional, Shchur, Sergey G, additional, Sazonov, Denis V, additional, Babenko, Larisa, additional, Bayandina, Elena, additional, Yarmoschuk, Asya, additional, Baliazin, Victor A, additional, Baliazina, Elena, additional, Budaeva, Elena, additional, Chernikova, Irina, additional, Goncharova, Zoya, additional, Krasnov, Vladimir, additional, Myatleva, Marina, additional, Rodionova, Olga V., additional, Samulyzhko, Iuliana, additional, Timofeeva, Alla A., additional, Duran, Sabas Boyero, additional, Bilbao, Maria Mar Mendibe, additional, Cuervo, Irene Diaz, additional, Domingo, Jose Maria Losada, additional, Eizaguirre, Amaia Gonzalez, additional, Llona, Jose Eulalio Barcena, additional, Moyano, Roberto Valverde, additional, Bahamonde, Carmen, additional, Lopez, Fernando Sanchez, additional, Morales, Raquel Pinar, additional, Morales, Eduardo Agüera, additional, Roman, Carmen Bahamonde, additional, Sepulveda, Juan Jose Ochoa, additional, Valero, Maria del Carmen Blanco, additional, Viña, Nazaret Pelaez, additional, Gavilan, Cristina Conde, additional, Sanchez, Ana Maria Jover, additional, Bedmar, Sara Vila, additional, Garcia, Nuria Gonzalez, additional, Garcia, Aida Orviz, additional, Gonzalez-Suarez, Ines, additional, Guillamon, Elena Miñano, additional, Kawiorski, Miguel, additional, Schulz, Elena Guerra, additional, Alonso, Alba Garcia, additional, Perez, Francisco Jesus Lopez, additional, Sarmiento, Marta Palacios, additional, Ayuso, Guillermo Izquierdo, additional, Mascarell, Guillermo Navarro, additional, Camino, Cristina Paramo, additional, Garcia, Asuncion Varas, additional, Mendoza, Yaiza Montserrat, additional, Muñoz, Veronica Ines Vargas, additional, Tonda, Patricia Torres, additional, Tsai, Ching-Piao, additional, Yin, Jiu-Haw, additional, Chen, Mei-Jung, additional, Li, Shan-Ni, additional, Wang, Fei-Ti, additional, Srisuwannanukorn, Suwat, additional, Boonmongkol, Thanatat, additional, Borisutbuathip, Duangporn, additional, Singwicha, Duangkamol, additional, Siritanan, Krittika, additional, Thearapati, Chidchanoke, additional, Sornda, Kwanmuang, additional, Apiwattanakul, Metha, additional, Aungsumart, Saharat, additional, Suanprasert, Narupat, additional, Suksuchano, Kaona, additional, Parkinsee, Nittaya, additional, Kulkantrakorn, Kongkiat, additional, Lolekha, Praween, additional, Potigumjon, Artit, additional, Sukphulloprat, Puchit, additional, Suksasunee, Dararat, additional, Komaratat, Chankawee, additional, Luangtong, Sunattana, additional, Arayawichanont, Arkhom, additional, Konpan, Phanpaphon, additional, Riablershirun, Nathapol, additional, Wiroteurairuang, Thaddao, additional, Jantaweesirirat, Panadda, additional, Kurne, Aslı, additional, Erkent, Irem, additional, Kurt, Ebru Bekircan, additional, Saylam, Ezgi, additional, Caliskan, Yagmur, additional, Orsel, Gulsah, additional, Celik, Yahya, additional, Celebi, Canan, additional, Tekatas, Aslan, additional, Banbal, Tugce, additional, Demir, Gulsen Akman, additional, Altunrende, Burcu, additional, Matur, Zeliha, additional, Topcular, Baris, additional, Elmas, Tules, additional, Gulo, Aysenur, additional, Ozdemir, Selin, additional, Ozkoklesen, Cansu, additional, Ozturk, Mahinur, additional, Yanik, Mertkan, additional, Yildirim, Elif, additional, Tutuncu, Melih, additional, Altintas, Ayse, additional, Cam, Abdulsamet, additional, Elmali, Ayse Deniz, additional, Saip, Sabahattin, additional, Siva, Aksel, additional, Tanrıverdi, Uygur, additional, Uygunoglu, Ugur, additional, Caliskan, Sinem, additional, Gulo, Pinar, additional, Kozig, Esra, additional, Sakiz, Sakine, additional, Sengun, Ihsan Sukru, additional, Idiman, Egemen, additional, Ala, Rahmi Tumay, additional, Arslan, Duygu, additional, Bulut, Utku, additional, Karakaptan, Yasemin, additional, Kaya, Derya, additional, Mehdiyev, Zaur, additional, Balkan, Bengu, additional, Kuku, Berfu, additional, Ozhun, Mujgan, additional, Tuga, Celal, additional, Ugur, Muzeyyen, additional, Efendi, Husnu, additional, Bunul, Sena Destan, additional, Cavus, Hakan, additional, Gorke, Yunus Emre, additional, Kutlu, Ayse, additional, Ozturk, Seda, additional, Sarikaya, Cansu Egilmez, additional, Becerikli, Gulsah, additional, Semiz, Cansu, additional, Tun, Ozlem, additional, Ayer, Sehriban, additional, Onar, Musa Kazim, additional, Ozberk, Mehlika Berra, additional, Sen, Sedat, additional, Cavdar, Tugce Kirbas, additional, Veske, Adife, additional, Boz, Cavit, additional, Altiparmak, Didem, additional, Aydin, Cigdem Ozen, additional, Gazioglu, Sibel, additional, Bekircan, Duygu, additional, Jacob, Anu, additional, Arndt, Heike, additional, Elsone, Liene, additional, Hamid, Shahd Hassan Mahmoud, additional, Whittam, Daniel Hugh, additional, Wilson, Martin, additional, O'Brien, Imelda, additional, Leite, Maria Isabel da Silva, additional, Cruz, Pedro Maria Rodriguez, additional, Jenkins, Damian Robert, additional, Tackley, George, additional, Cavey, Ana, additional, Everett, Rosie, additional, Hodder, Joy, additional, Koelewyn, Abigail, additional, Mowry, Ellen, additional, Royal, Walter, additional, Shin, Robert, additional, Bever, Christopher, additional, Harrison, Daniel, additional, Rus, Horea, additional, Zheng, Wei, additional, Callison, Karen, additional, Naunton, Kerry, additional, Frishberg, Benjamin M, additional, Blumenfeld, Andrew M, additional, Inocelda, Andrew, additional, Korabathina, Kalyani, additional, Lobatz, Michael, additional, Mortin, Melissa M, additional, Oh, Irene J, additional, Rosenberg, Jay H, additional, Sadoff, Mark, additional, Sahagian, Gregory A, additional, Wang, Anchi, additional, Camberos, Yasmin, additional, Sanchez, Guadalupe, additional, Soto, Estela, additional, Nicholas, Jacqueline A, additional, Boster, Aaron, additional, Eubank, Geoffrey, additional, Groezinger, Katy, additional, Lauf, Meghan, additional, Okai, Annette F, additional, Hasan, Rashedul, additional, Khoury, Chaouki, additional, Stokes, Victoria, additional, Clardy, Stacey, additional, Cortez, Melissa, additional, Greenlee, John, additional, Rose, John, additional, Soldan, Mateo Paz, additional, Emett, Amanda, additional, Esquibel, Lawanda, additional, Fagatele, Lilly, additional, Wong, Ka-Ho, additional, Stevens, James C, additional, Banas, Thomas M, additional, Bultemeyer, Marlene C, additional, Haller, Andrea, additional, Manalo, Natalie, additional, Aeschliman, Keri, additional, Kocks, Debi, additional, Racke, Michael, additional, Boster, Aaron Lee, additional, Bowman, Michelle, additional, Imitola, Jaime, additional, Kisanuki, Yasushi, additional, Green, Misty, additional, Scarberry, Stephanie, additional, Lynch, Sharon G, additional, Anderson, Heather S, additional, Gronseth, Gary S, additional, Hammond, Nancy E, additional, Jassam, Yasir N, additional, Mittal, Manoj K, additional, Nashatizadeh, Muhammed M, additional, Levine, Nicholas, additional, Schmidt, Lisa, additional, Sibley, Jill, additional, Whitley, Vonda, additional, Winkley, James, additional, Coleman, Timothy, additional, Cooper, Gregory, additional, Sheffield, Stephanie, additional, Turner, Keri, additional, Galloway, Dana, additional, Tillett, Robert S, additional, Ganesh, Geeta A, additional, Plato, Brian M, additional, Seifert, Tad D, additional, Godwin, Diana, additional, Lockridge, Deborah, additional, Rammohan, Kottil W, additional, Sheremata, William A, additional, Delgado, Silvia, additional, Gonzalez, Jose, additional, Lizarraga, Alexis, additional, Maldonado, Janice, additional, Ortega, Melissa, additional, Tornes, Leticia, additional, Babcock, Yanet, additional, Cailam, Osmara, additional, Campos, Yesica, additional, Couvertier, Irlisse, additional, Daneri, Bettina, additional, Deni, Jeremy, additional, Hernandez, Jeffrey, additional, Jaramillo, Tatiana, additional, Morris, Tenita, additional, Nobel, Daniel, additional, Oliveira, Anjelis, additional, Richardson, Reshma, additional, Rodriguez, Gloria, additional, Romero, Ana, additional, Sandova, Carlos, additional, Sawant, Ruta, additional, Tueros, Lissett, additional, Zetka, Eric S, additional, Zheng, Chao, additional, Jacobs, Daniel H, additional, Easterling, Constance, additional, Fairbank, Jennifer, additional, Iyengar, Revathi, additional, Klafter, Mark, additional, Lindquist, Justin, additional, Sadek, Ahmed H, additional, Toro, Elizabeth Carmona, additional, Verma, Navin, additional, Castro, Brigith Patino, additional, Sukhraj-Singh, Nadia, additional, Berger, Joseph, additional, Williamson, Eric, additional, Chahin, Salim, additional, Jacobs, Dina, additional, Markowitz, Clyde, additional, Dobbins, Jessica, additional, Mace, Lauren, additional, Martin, Maria, additional, Pinckney, Ashley, additional, Roberts, Amber, additional, Zaydan, Islam, additional, Mitchell, Galen W, additional, Heyman, Rock A, additional, Orie, Ryan L, additional, Suski, Valerie R, additional, Oddis, Kerry, additional, Punjack, Darlene, additional, Flanagan, Eoin, additional, Gadoth, Avi, additional, McKeon, Andrew, additional, Tobin, W Oliver, additional, Zekeridou, Anastasia, additional, Dunlay, Katie, additional, Sagen, Jessica, additional, Carter, Jonathan L, additional, Estephan, Bachir, additional, Goodman, Brent P, additional, Snyder, Charlene R Hoffman, additional, Francone, Andrea, additional, Galasky, Irene, additional, Thomas, Martha, additional, Repovic, Pavle, additional, Bowen, James, additional, Mayadev, Angeli, additional, Qian, Peiqing, additional, Courtney, Yuriko, additional, Lennox, Lauren, additional, Naismith, Robert Thomas, additional, Cross, Anne Haney, additional, Evans, Emily, additional, Longbrake, Erin E, additional, Orchard, Megan E, additional, Wu, Gregory F, additional, Heinrich, Linda, additional, Sommers, Susan, additional, Amjad, Faria, additional, Mitchell, Erika, additional, Mora, Carlos, additional, Schreiber, Bethany, additional, Tornatore, Carlo, additional, Carlson, Alexis, additional, McCarthy, Sacha, additional, and Oliver, Alexandria, additional

Published
2021
Full Text
View/download PDF

25. Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ

Author

Waddington, Kirsty E., primary, Papadaki, Artemis, additional, Coelewij, Leda, additional, Adriani, Marsilio, additional, Nytrova, Petra, additional, Kubala Havrdova, Eva, additional, Fogdell-Hahn, Anna, additional, Farrell, Rachel, additional, Dönnes, Pierre, additional, Pineda-Torra, Inés, additional, and Jury, Elizabeth C., additional

Published
2020
Full Text
View/download PDF

27. Activation of the liver X receptors alters CD4+ T cell membrane lipids and signalling through direct regulation of glycosphingolipid synthesis

Author

Waddington, Kirsty E, Robinson, George A, Adriani, Marsilio, Rubio-Cuesta, Beatriz, Chrifi-Alaoui, Eden, Andreone, Sara, Poon, Kok-Siong, Ivanova, Iveta, Martin-Gutierrez, Lucia, Owen, Dylan M, Nytrova, Petra, Havrdova, Eva Kubala, Farrell, Rachel, Jury, Elizabeth C, and Pineda-Torra, Inés

Subjects
lipids (amino acids, peptides, and proteins), digestive system
Abstract

Summary Liver X Receptors (LXRs) are important transcriptional regulators of intracellular cholesterol, fatty acid, and phospholipid levels. LXRs can dampen inflammation in macrophages by promoting cholesterol efflux and altering plasma membrane lipid rafts; microdomains enriched for cholesterol and glycosphingolipids that regulate immune-cell signalling. However, little is known about the impact of LXR activators on T cell plasma membrane lipid rafts, which are critical for T-cell antigen receptor (TCR) signalling. Here we show that the LXR synthetic agonist GW3965 significantly increases glycosphingolipid levels and reduces cholesterol and lipid order (stability) in the plasma membrane of human CD4 + T cells. Moreover, the GSL biosynthesis enzyme UGCG was identified as a novel direct target of LXR activation. Importantly, LXR-mediated changes in T cell lipid composition were associated with altered spatiotemporal distribution of lipids and signalling molecules at the immune synapse. Crucially, LXR activation altered the kinetics of proximal TCR-signalling events in activated T cells, reduced T cell proliferation and enhanced the production of IL-2 and IL-4. Thus, LXR activation influences T cell function via alteration of the plasma membrane lipid profile. Finally, the expression of UGCG and other LXR-regulated genes and lipids was significantly dysregulated in T-cells isolated from people with multiple sclerosis. Overall, a novel action of LXR has been characterised that involves modulation of lipid raft-associated cholesterol and glycosphingolipids in CD4 + T-cells, which could be of therapeutic relevance in multiple sclerosis.

Published
2019
Full Text
View/download PDF

28. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Author

Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Eva Kubala Havrdova, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, Mccombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse, Soysal, Aysun, Vucic, Steve, Grand-Maison, Francois, Eichau Madueno, Sara, Izquierdo Ayuso, Guillermo, Lugaresi, Alessandra, Onofrj, Marco, Trojano, Maria, Marriott, Mark, Butzkueven, Helmut, Kister, Ilya, and Kalincik, Tomas

Published
2019

29. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Author

Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Kunchok, Amy; Malpas, Charles; Nytrova, Petra; Havrdova, Eva; Alroughani, Raed; Terzi, Murat; Yamout, Bassem; Hor, Jyh Yung; Karabudak, Rana; Boz, Cavit; Özakbaş, Serkan; Olascoaga Urtaza, Francisco Javier; Simo, Magdolna; Granella, Franco; Patti, Francesco; McCombe, Pamela; Csepany, Tunde; Singhal, Bhim; Bergamaschi, Roberto; Fragoso, Yara; Al-Harbi, Talal; Türkoğlu, Recai; Lechner-Scott, Jeannette; Laureys, Guy; Oreja-Guevara, Celia; Pucci, Eugenio; Sola, Patrizia; Ferraro, Diana; Soysal, Aysun; Vucic, Steve; Grand-Maison, Francois; Eichau Madueno, Sara; Izquierdo Ayuso, Guillermo; Lugaresi, Alessandra; Onofrj, Marco; Trojano, Maria; Marriott, Mark; Butzkueven, Helmut; Kister, Ilya; Kalincik, Tomas, School of Medicine, Department of Neurology, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Kunchok, Amy; Malpas, Charles; Nytrova, Petra; Havrdova, Eva; Alroughani, Raed; Terzi, Murat; Yamout, Bassem; Hor, Jyh Yung; Karabudak, Rana; Boz, Cavit; Özakbaş, Serkan; Olascoaga Urtaza, Francisco Javier; Simo, Magdolna; Granella, Franco; Patti, Francesco; McCombe, Pamela; Csepany, Tunde; Singhal, Bhim; Bergamaschi, Roberto; Fragoso, Yara; Al-Harbi, Talal; Türkoğlu, Recai; Lechner-Scott, Jeannette; Laureys, Guy; Oreja-Guevara, Celia; Pucci, Eugenio; Sola, Patrizia; Ferraro, Diana; Soysal, Aysun; Vucic, Steve; Grand-Maison, Francois; Eichau Madueno, Sara; Izquierdo Ayuso, Guillermo; Lugaresi, Alessandra; Onofrj, Marco; Trojano, Maria; Marriott, Mark; Butzkueven, Helmut; Kister, Ilya; Kalincik, Tomas, School of Medicine, and Department of Neurology

Abstract

NA

Published
2019

30. Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder (P1.2-072)

Author

Kunchok, Amy, primary, Malpas, Charles, additional, Nytrova, Petra, additional, Havrdova, Eva, additional, Alroughani, Raed, additional, Terzi, Murat, additional, Yamout, Bassem, additional, Hor, Jyh Yung, additional, Karabudak, Rana, additional, Boz, Cavit, additional, Ozakbas, Serkan, additional, Urtaza, Francisco Javier Olascoaga, additional, Simo, Magdolna, additional, Granella, Franco, additional, Patti, Francesco, additional, McCombe, Pamela, additional, Csepany, Tunde, additional, Singhal, Bhim, additional, Bergamaschi, Roberto, additional, Fragoso, Yara, additional, Al-Harbi, Talal, additional, Turkoglu, Recai, additional, Lechner-Scott, Jeannette, additional, Laureys, Guy, additional, Oreja-Guevara, Celia, additional, Pucci, Eugenio, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Altintas, Ayse, additional, Soysal, Aysun, additional, Vucic, Steve, additional, Grand-Maison, Francois, additional, Madueno, Sara Eichau, additional, Ayuso, Guillermo Izquierdo, additional, Lugaresi, Alessandra, additional, Onofrj, Marco, additional, Trojano, Maria, additional, Marriott, Mark, additional, Butzkueven, Helmut, additional, Kister, Ilya, additional, and Kalincik, Tomas, additional

Published
2019
Full Text
View/download PDF

31. Monocyte NOTCH2 expression predicts IFN-beta immunogenicity in multiple sclerosis patients

Author

Adriani, Marsilio, Nytrova, Petra, Mbogning, Cyprien, Hassler, Signe, Medek, Karel, Jensen, Poul Erik H., Creeke, Paul, Warnke, Clemens, Ingenhoven, Kathleen, Hemmer, Bernhard, Sievers, Claudia, Gasser, Raija L. P. Lindberg, Fissolo, Nicolas, Deisenhammer, Florian, Bocskei, Zsolt, Mikol, Vincent, Fogdell-Hahn, Anna, Havrdova, Eva Kubala, Broet, Philippe, Donnes, Pierre, Mauri, Claudia, Jury, Elizabeth C., Adriani, Marsilio, Nytrova, Petra, Mbogning, Cyprien, Hassler, Signe, Medek, Karel, Jensen, Poul Erik H., Creeke, Paul, Warnke, Clemens, Ingenhoven, Kathleen, Hemmer, Bernhard, Sievers, Claudia, Gasser, Raija L. P. Lindberg, Fissolo, Nicolas, Deisenhammer, Florian, Bocskei, Zsolt, Mikol, Vincent, Fogdell-Hahn, Anna, Havrdova, Eva Kubala, Broet, Philippe, Donnes, Pierre, Mauri, Claudia, and Jury, Elizabeth C.

Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by CNS inflammation leading to demyelination and axonal damage. IFN-beta is an established treatment for MS; however, up to 30% of IFN-beta-treated MS patients develop neutralizing antidrug antibodies (nADA), leading to reduced drug bioactivity and efficacy. Mechanisms driving antidrug immunogenicity remain uncertain, and reliable biomarkers to predict immunogenicity development are lacking. Using high-throughput flow cytometry, NOTCH2 expression on CD14(+) monocytes and increased frequency of proinflammatory monocyte subsets were identified as baseline predictors of nADA development in MS patients treated with IFN-beta. The association of this monocyte profile with nADA development was validated in 2 independent cross-sectional MS patient cohorts and a prospective cohort followed before and after IFN-beta administration. Reduced monocyte NOTCH2 expression in nADA(+) MS patients was associated with NOTCH2 activation measured by increased expression of Notch-responsive genes, polarization of monocytes toward a nonclassical phenotype, and increased proinflammatory IL-6 production. NOTCH2 activation was T cell dependent and was only triggered in the presence of serum from nADA(+) patients. Thus, nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-beta administration.

Published
2018

32. Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients

Author

Adriani, Marsilio, primary, Nytrova, Petra, additional, Mbogning, Cyprien, additional, Hässler, Signe, additional, Medek, Karel, additional, Jensen, Poul Erik H., additional, Creeke, Paul, additional, Warnke, Clemens, additional, Ingenhoven, Kathleen, additional, Hemmer, Bernhard, additional, Sievers, Claudia, additional, Lindberg Gasser, Raija L.P., additional, Fissolo, Nicolas, additional, Deisenhammer, Florian, additional, Bocskei, Zsolt, additional, Mikol, Vincent, additional, Fogdell-Hahn, Anna, additional, Kubala Havrdova, Eva, additional, Broët, Philippe, additional, Dönnes, Pierre, additional, Mauri, Claudia, additional, and Jury, Elizabeth C., additional

Published
2018
Full Text
View/download PDF

33. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T

Author

Sinnecker, Tim, primary, Schumacher, Sophie, additional, Mueller, Katharina, additional, Pache, Florence, additional, Dusek, Petr, additional, Harms, Lutz, additional, Ruprecht, Klemens, additional, Nytrova, Petra, additional, Chawla, Sanjeev, additional, Niendorf, Thoralf, additional, Kister, Ilya, additional, Paul, Friedemann, additional, Ge, Yulin, additional, and Wuerfel, Jens, additional

Published
2016
Full Text
View/download PDF

34. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

Author

Waters, Patrick, primary, Reindl, Markus, additional, Saiz, Albert, additional, Schanda, Kathrin, additional, Tuller, Friederike, additional, Kral, Vlastimil, additional, Nytrova, Petra, additional, Sobek, Ondrej, additional, Nielsen, Helle Hvilsted, additional, Barington, Torben, additional, Lillevang, Søren T, additional, Illes, Zsolt, additional, Rentzsch, Kristin, additional, Berthele, Achim, additional, Berki, Tímea, additional, Granieri, Letizia, additional, Bertolotto, Antonio, additional, Giometto, Bruno, additional, Zuliani, Luigi, additional, Hamann, Dörte, additional, van Pelt, E Daniëlle, additional, Hintzen, Rogier, additional, Höftberger, Romana, additional, Costa, Carme, additional, Comabella, Manuel, additional, Montalban, Xavier, additional, Tintoré, Mar, additional, Siva, Aksel, additional, Altintas, Ayse, additional, Deniz, Günnur, additional, Woodhall, Mark, additional, Palace, Jacqueline, additional, Paul, Friedemann, additional, Hartung, Hans-Peter, additional, Aktas, Orhan, additional, Jarius, Sven, additional, Wildemann, Brigitte, additional, Vedeler, Christian, additional, Ruiz, Anne, additional, Leite, M Isabel, additional, Trillenberg, Peter, additional, Probst, Monika, additional, Saschenbrecker, Sandra, additional, Vincent, Angela, additional, and Marignier, Romain, additional

Published
2016
Full Text
View/download PDF

36. Assessment of aquaporin-4 (AQP4) antibody assays in European diagnostic centres

Author

Waters, Patrick, primary, Reindl, Markus, additional, Schanda, Kathrin, additional, Tuller, Friederike, additional, Kral, Vlastimil, additional, Nytrova, Petra, additional, Sobek, Ondrej, additional, Nielsen, Helle Hvilsted, additional, Illés, Zsolt, additional, Barington, Torben, additional, Lillevang, Søren Thue, additional, Stöcker, Winfried, additional, Rentzsch, Kristin, additional, Probst, Christian, additional, Saschenbrecker, Sandra, additional, Klingbeil, Christine, additional, Krummrei, Ulrike, additional, Berthele, Achim, additional, Berki, Timea, additional, Granieri, Letizia, additional, Bertolotto, Antonio, additional, Giometto, Bruno, additional, Zuliani, Luigi, additional, Hamann, Dörte, additional, Saiz, Albert, additional, Höftberger, Romana, additional, Comabella, Manuel, additional, Riu, Carme Costa, additional, Siva, Aksel, additional, Altintas, Ayse, additional, Deniz, Günnur, additional, Vincent, Angela, additional, Leite, M. Isabel, additional, Woodhall, Mark, additional, Palace, Jacqueline, additional, Paul, Friedemann, additional, Aktas, Orhan, additional, Jarius, Sven, additional, Vedeler, Christian, additional, Ruiz, Anne, additional, and Marignier, Romain, additional

Published
2014
Full Text
View/download PDF

41. Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.

Author

Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, and Monif M

Subjects
Humans, Female, Male, Adult, Retrospective Studies, Middle Aged, Prevalence, Cohort Studies, Disability Evaluation, Neuromyelitis Optica immunology, Neuromyelitis Optica epidemiology, Aquaporin 4 immunology, Immunoglobulin G blood, Disease Progression, Recurrence, Autoantibodies blood
Abstract

Objectives: In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD., Methods: This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results., Results: A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%)., Discussion: This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.

Published
2024
Full Text
View/download PDF

42. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.

Author

Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, and Monif M

Abstract

Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD., Methods: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate., Results: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group., Conclusion: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus., Competing Interests: Competing interests: The author(s) would like to disclose the following. PSiriratnam has received travel support from Novartis and Biogen; AvdW has received travel support and served on advisory boards for Novartis, Biogen, Merck Serono, Roche and Teva, she receives grant support from the National Health and Medical Research Council of Australia; HB served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and received conference travel support from Novartis, Biogen and Sanofi Aventis, he serves on steering committees for trials conducted by Biogen and Novartis and received research support from Merck, Novartis and Biogen, Medical Research Council and MS Research Australia; YCF has received travel support from Roche and Biogen, he receives grant support from Australian National Health Medical Research Council, Australia and New Zealand Association of Neurologists, AVANT foundation and MS Research Australia; WZY has received speaker honoraria from Merck and Novartis; CZ receives fellowship from the Trish Multiple Sclerosis Research Foundation; VJ receives fellowship and research support from the National Health and Medical Research Council of Australia, she also receives research grant support form F.Hoffmann La-Roche and the International Progressive MS Alliance; SH receives research support from academic entity - National Institute for Health Research (NIHR304529): Research funding; MM has served on advisory board for Merck, and Novartis and has received speaker honoraria from Merck, Biogen and Novartis, her institution receives funding from Merck, Australian National Health; TK served on scientific advisory boards for MS International Federation and WHO, BMS, Roche, Janssen, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Roche, Sanofi-Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck; SJK received compensation for scientific advisory board activity from Merck and Roche, and received compensation for serving on the IDMC for Biogen; TC received speaker honoraria/conference travel support from Biogen, Merck, Novartis, Roche, Sanofi-Aventis and Teva; BW received honoraria for acting as a member of Scientific Advisory Boards/Consultancy for Alexion, Almirall, Biogen, Celgene/BMS, Merck, Janssen, Novartis, Roche, Sandoz, Sanofi-Genzyme and speaker honoraria and travel support from Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme, research and/or patient support grants from Biogen, Janssen, Merck, Sanofi-Genzyme, Roche, Honoraria and grants were paid to UZA/UZA Foundation, further, B.W. received research funding from FWO-TBM, Belgian Charcot Foundation, Start2Cure Foundation, Queen Elisabeth Medical Foundation for Neurosciences and the National MS Society USA; PN received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Roche, Jannsen, Astra Zeneca and financial support for research activities from Roche and Merck, the work of PN was supported by Ministry of Health of the Czech Republic, grant nr. NU23-05-00462; AA received speaker honoraria from Novartis and Alexion; AA-A received personal compensation for serving as a Scientific Advisory or speaker/moderator for Novartis, Biogen, Roche, Sanofi-Genzyme, and Merck; BY received honoraria as a speaker and member of scientific advisory boards from Sanofi, Bayer, Biogen, Merck, Janssen, Novartis, Roche and Aspen; GL received travel and/or consultancy compensation from Sanofi-Genzyme, Roche, Teva, Merck, Novartis, Celgene, Biogen; FP received personal compensation for serving on advisory board by Almirall, Alexion, Biogen, Bristol, Janssen, Merck, Novartis and Roche, he further received research grant by Alexion, Almirall, Biogen, Bristol, Merck, Novartis and Roche and by FISM, Reload Association (Onlus), Italian Health Minister and University of Catania. Magdolna Simo received speaker honoraria from Novartis, Biogen, Bayer Schering, Sanofi, Merck, Roche, congress/travel compensation from Teva, Biogen, Merck, Bayer Schering Novartis, Roche; MF received travel and meeting attendance support from Novartis, Biogen, Roche, Sanofi-Genzyme and Merck; ASoysal received travel and meeting attendance support from Novartis, Biogen, Roche, Merck, Bristol, Sanofi-Genzyme, Almirall, Piam; PAM received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi and travel grants from Novartis, Biogen and Bayer Schering; RA received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche and Sanofi-Genzyme; JLS-M, accepted travel compensation from Novartis, Merck and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva and has participated in clinical trials by Biogen, Merck and Roche; JLS received travel compensation from Novartis, Biogen, Roche and Merck, her institution receives the honoraria for talks and advisory board commitment as well as research grants from Biogen, Merck, Roche, TEVA and Novartis., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

43. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T.

Author

Sinnecker T, Schumacher S, Mueller K, Pache F, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, Kister I, Paul F, Ge Y, and Wuerfel J

Abstract

Objective: To characterize paramagnetic MRI phase signal abnormalities in neuromyelitis optica spectrum disorder (NMOSD) vs multiple sclerosis (MS) lesions in a cross-sectional study., Methods: Ten patients with NMOSD and 10 patients with relapsing-remitting MS underwent 7-tesla brain MRI including supratentorial T2*-weighted imaging and supratentorial susceptibility weighted imaging. Next, we analyzed intra- and perilesional paramagnetic phase changes on susceptibility weighted imaging filtered magnetic resonance phase images., Results: We frequently observed paramagnetic rim-like (75 of 232 lesions, 32%) or nodular (32 of 232 lesions, 14%) phase changes in MS lesions, but only rarely in NMOSD lesions (rim-like phase changes: 2 of 112 lesions, 2%, p < 0.001; nodular phase changes: 2 of 112 lesions, 2%, p < 0.001)., Conclusions: Rim-like or nodular paramagnetic MRI phase changes are characteristic for MS lesions and not frequently detectable in NMOSD. Future prospective studies should ask whether these imaging findings can be used as a biomarker to distinguish between NMOSD- and MS-related brain lesions.

Published
2016
Full Text
View/download PDF

44. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.

Author

Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, Palace J, Wassmer E, Tardieu M, Vincent A, Lim M, and Waters P

Abstract

Objective: To determine whether myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) were predictive of a demyelination phenotype in children presenting with acquired demyelinating syndrome (ADS)., Method: Sixty-five children with a first episode of ADS (12 acute disseminated encephalomyelitis, 24 optic neuritis, 18 transverse myelitis, 11 other clinically isolated syndrome) were identified from 2 national demyelination programs in the United Kingdom and France. Acute serum samples were tested for MOG-Abs by cell-based assay. Antibodies were used to predict diagnosis of multiple sclerosis (MS) at 1 year., Results: Twenty-three of 65 (35%) children had MOG-Abs. Antibody-positive and antibody-negative patients were not clinically different at presentation, but identification of MOG-Abs predicted a non-MS course at 1-year follow-up: only 2/23 (9%) MOG-Ab-positive patients were diagnosed with MS compared to 16/42 (38%) MOG-Ab-negative patients (p = 0.019, Fisher exact test). Antibody positivity at outset was a useful predictor for a non-MS disease course, with a positive predictive value of 91% (95% confidence interval [CI] 72-99), negative predictive value of 38% (95% CI 24-54), positive likelihood ratio of 4.02 (CI 1.0-15.4), and odds ratio of 6.5 (CI 1.3-31.3)., Conclusions: MOG-Abs are found at presentation in 35% of patients with childhood ADS, across a range of demyelinating disorders. Antibody positivity can be useful in predicting a non-MS disease course at onset.

Published
2015
Full Text
View/download PDF

45. Coincidence of spinal tumor (astrocytoma) and non-specific encephalomyelitis.

Author

Burgetova A, Vaneckova M, Nytrova P, Matej R, and Seidl Z

Subjects
Adult, Biopsy, Diagnosis, Differential, Fatal Outcome, Humans, Magnetic Resonance Imaging, Male, Astrocytoma complications, Astrocytoma diagnosis, Encephalomyelitis complications, Encephalomyelitis diagnosis, Spinal Neoplasms complications, Spinal Neoplasms diagnosis
Abstract

The aim of this paper is to demonstrate that differential diagnostics of intra-medullary spinal lesions can sometimes be very difficult, even when the latest complement examinations are used, including magnetic resonance imaging. The particular case dealt with here was complicated by the presence of two different pathological processes. We present the case report, where the case history, clinical course and results of the paraclinical examinations, including the magnetic resonance imaging, suggested an intra-medullary inflammatory/demyelinating process. The post-mortem histological finding was a surprise, because besides signs of non-specific encephalomyelitis, it also displayed signs of a spinal tumor (histological character of diffuse astrocytoma grade II-III). We would like to emphasize some important facts in our discussion, especially from the perspective of the magnetic resonance imaging. Finally, we would like to ask if the presence of both pathologies (astrocytoma and nonspecific myelitis) was coincidental, or if the myelitis had an iatrogenic etiology (by therapy, by infection during the lumbar punctions).

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results